Cell Therapeutics finds new CMO; Osiris touts another nod for stem cell drug;

@FierceBiotech: Devicemakers should rely more upon outsourcing and CROs, study says. Report | Follow @FierceBiotech

@JohnCFierce: Just heard we sold out on the 330-seat venue for our R&D breakfast in Boston Tuesday. Which is pretty cool. Hope to see you there. | Follow @JohnCFierce

@RyanMFierce: Some lab and IT workers targeted in 400 layoffs at AstraZeneca in Sweden. Item | Follow @RyanMFierce

> Cell Therapeutics ($CTIC) has named Dr. Steven Benner, formerly of OncoMed Pharmaceuticals, as the company's new chief medical officer. Release

> Osiris Therapeutics ($OSIR) can now say that its stem cell therapy Prochymal is approved in two countries for graft-versus-host disease in children. The drug won approval in New Zealand, following the historic nod in Canada earlier this year. Release

> Regeneron Pharmaceuticals' ($REGN) shares lost ground after a rival to the biotech company's Eylea for wet age-related macular degeneration reported positive results from a trial. Report

Pharma News

@FiercePharma: Big Pharma's Japanese sales gain as U.S., Europe lag. News | Follow @FiercePharma

> Austerity, generics push Lundbeck to cut 600 jobs. More

> Who'll be the biggest drugmaker of them all? Report

> Heart docs skeptical of new-generation clotbusters. Article

Medical Devices News

@FierceMedDev: Invuity says its $25M series D round comes even as surgical tools aren't otherwise drawing much investor interest. Item | Follow @FierceMedDev

@MarkHFierce:  We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

> Armed with CE mark, Dexcom rolls out next-gen glucose monitor. Article

> Edwards' stock soars after FDA panel nod on expanded Sapien valve use. Story

> MIT's fuel cell uses glucose to power brain implants. News

> JustRight, maker of a tissue-sealing device, grabs $6.5M. Item

CRO News

@NesaNFierce: FierceCRO just posted its Top 5 Strategic CRO/Pharma Partnerships list! Check it out and let me know what you think! Special Report | Follow @NesaNFierce

> Eli Lilly bets on insulin research and generics manufacturing in China. Article

> Former Sandia employee faces embezzlement charges after stealing nanotech info. Story

> Devicemakers should rely more upon outsourcing and CROs, study says. More

> Zeincro Group and Trial Masters merge to expand Eastern European reach. Report

Pharma Manufacturing News

@EricPFierce: Filtrona completes its acquisition of Lymtech Scientific. News | Follow @EricPFierce

> Smaller Indian drugmakers need support to improve GMPs. Item

> Cuts in drug manufacturing felt in U.K. industrial output. Article

> Loss for CMO Patheon smaller than expected. Story

> Pakistan's ex-health director has heart attack under questioning. Report

Vaccines News

> GeoVax: Meeting the HIV vaccine challenge. Column

> VaxInnate bird flu shot flies into Phase I. More

> Novartis, Cytos Alzheimer's vax shows immune response. Item

> New HPV vax could treat cancer rather than prevent it. News

And Finally… A 10-year analysis of women with diabetes found that those on the drug metformin had a 25% reduced risk of getting breast cancer. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.